Highlights Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-15 pm EDT			5-day change	1st Jan Change
5.190 ^USD	+5.70%		+8.81%	-15.61%

Apr. 14	Myriad Genetics Secures Japanese Regulatory Approval For Prostate Cancer Diagnostic Test	MT
Apr. 14	Myriad Genetics Inc Expands Access For Mychoice Test To Prostate Cancer Patients In Japan	CI

Highlights

Apr. 14	Myriad Genetics Inc Expands Access For Mychoice Test To Prostate Cancer Patients In Japan	CI
Apr. 09	Myriad Genetics Announces New Data Presentations At Society of Gynecologic Oncology Annual Meeting	CI
Mar. 17	Myriad Genetics Gets US FDA Approval of MyChoice as Companion Diagnostic for Ovarian Cancer Drug	MT
Mar. 17	Myriad Genetics, Inc. Announces FDA Approval Of The MyChoice CDx Test As Companion Diagnostic For Zejula For Patients With Ovarian Cancer	CI
Mar. 02	Myriad Genetics, Inc. Announces the Launch of the Precise MRD	CI
Feb. 24	Myriad Genetics Inc files for mixed shelf of up to $200 million - SEC filing	RE
Feb. 24	Myriad Genetics, Inc. to Present New Data At the 2026 Asco-Gu Conference Supporting Its Precise Mrd, Prolaris,®? Prostate Cancer Prognostic Test and Myrisk Hereditary Cancer Tests	CI
Feb. 24	Top Premarket Gainers	MT
Feb. 23	Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 23	Myriad Genetics, Inc. Provides Earnings Guidance for the First Quarter and Second Half of 2026; Reiterate Earnings Guidance for the Full Year 2026	CI
Feb. 19	Myriad Genetics, Inc. Announces the Publication of the Analytical Validation of the Firstgene Multiple Prenatal Screen in Clinical Chemistry	CI
Jan. 27	Myriad Genetics, Inc. Advances Mrd Commercialization Timeline, Bolstered by New Study Data	CI
Jan. 12	Myriad Genetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 and 2026	CI
Jan. 12	Myriad Genetics announces select preliminary fourth quarter and full year 2025 financial results and introduces full year 2026 financial guidance	RE
Dec. 19	Zydus Lifesciences Signs Pact to Launch Cancer-Risk Assessment Diagnostic Tests in India	MT
Dec. 18	Zydus Lifesciences Limited Signs an Exclusive Agreement with Myriad Genetics	CI
Nov. 25	Clairity, Myriad Genetics, Inc. and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health	CI
Nov. 10	Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk®? Hereditary Cancer Test to Support Evolving Clinical Needs	CI
Nov. 06	Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference	CI
Nov. 03	Myriad Genetics Q3 revenue beats on volume growth in hereditary cancer testing	RE
Nov. 03	Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full-Year 2025	CI
Nov. 03	Myriad Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-31	Myriad Genetics, Inc. Announces A Post-Hoc Analysis of the Precision Medicine in Mental Health Care Study	CI
25-10-15	Kringle Pharma Establishes US Subsidiary to Accelerate Spinal Cord Injury Program	MT
25-10-14	Myriad Genetics, Inc. Adds F8, FXN Genes to Foresight Universal Plus Panel	CI